All In Biotech

Drug Trial Radar · NCT03344458

A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial

enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

298

Actual

Start

Dec 19, 2017

Primary completion

Feb 21, 2023

Study completion Feb 21, 2023

Sponsor

Lead sponsor
Ascendis Pharma A/SIndustry
Sponsor type
Industry
First posted
Nov 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Poland, Bulgaria, Ukraine, Armenia, Russia and Australia.

Conditions

  • Growth Hormone Deficiency, Pediatric
  • Endocrine System Diseases
  • Hormone Deficiency
  • Pituitary Diseases

Interventions

  • TransCon hGHDrug

    Once weekly subcutaneous injection of TransCon hGH

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With Treatment-Emergent Adverse Events [Long-Term Safety and Tolerability]Time frame: Up to Week 208

Locations

42 sites in 11 countries. Site status is shown where the registry gives one.

  • Ascendis Pharma Investigational Site

    Birmingham, Alabama

  • Ascendis Pharma Investigational Site

    Los Angeles, California

  • Ascendis Pharma Investigational Site

    Orange, California

  • Ascendis Pharma Investigational Site

    Sacramento, California

  • Ascendis Pharma Investigational Site

    Centennial, Colorado

  • Ascendis Pharma Investigational Site

    Jacksonville, Florida

  • Ascendis Pharma Investigational Site

    Orlando, Florida

  • Ascendis Pharma Investigational Site

    Tallahassee, Florida

  • Ascendis Pharma Investigational Site

    Saint Paul, Minnesota

  • Ascendis Pharma Investigational Site

    Jackson, Mississippi

  • Ascendis Pharma Investigational Site

    Lebanon, New Hampshire

  • Ascendis Pharma Investigational Site

    Mineola, New York

  • Ascendis Pharma Investigational Site

    New York, New York

  • Ascendis Pharma Investigational Site

    Cleveland, Ohio

  • Ascendis Pharma Investigational Site

    Oklahoma City, Oklahoma

  • Ascendis Pharma Investigational Site

    Portland, Oregon

  • Ascendis Pharma Investigational Site

    Portland, Oregon

  • Ascendis Pharma Investigational Site

    Dallas, Texas

  • Ascendis Pharma Investigational Site

    Fort Worth, Texas

  • Ascendis Pharma Investigational Site

    Charlottesville, Virginia

  • Ascendis Pharma Investigational Site

    Norfolk, Virginia

  • Ascendis Pharma Investigational Site

    Tacoma, Washington

  • Ascendis Pharma Investigational Site

    Yerevan, Armenia

  • Ascendis Pharma Investigational Site

    Clayton, Victoria, Australia

  • Ascendis Pharma Investigational Site

    Minsk, Belarus

  • Ascendis Pharma Investigational Site

    Varna, Bulgaria

  • Ascendis Pharma Investigational Site

    Tbilisi, Georgia

  • Ascendis Pharma Investigational Site

    Athens, Greece

  • Ascendis Pharma Investigational Site

    Auckland, New Zealand

  • Ascendis Pharma Investigational Site

    Gdansk, Poland

  • Ascendis Pharma Investigational Site

    Warsaw, Poland

  • Ascendis Pharma Investigational Site

    Izhevsk, Russia

  • Ascendis Pharma Investigational Site

    Krasnoyarsk, Russia

  • Ascendis Pharma Investigational Site

    Moscow, Russia

  • Ascendis Pharma Investigational Site

    Saint Petersburg, Russia

  • Ascendis Pharma Investigational Site

    Saratov, Russia

  • Ascendis Pharma Investigational Site

    Ufa, Russia

  • Ascendis Pharma Investigational Site

    Vologda, Russia

  • Ascendis Pharma Investigational Site

    Voronezh, Russia

  • Ascendis Pharma Investigational Site

    Kharkiv, Ukraine

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.